PXD101

PXD101 is an anti-angiogenesis drug designed for mesothelioma patients whose cancer cannot be removed by surgery. Administered orally, PXD101 is a histone deacetylase inhibitor that is used as a second line therapy. The drug is believed to stop tumor growth by inhibiting enzymes necessary for cell growth and by blocking blood flow to the tumor.

PXD101 is currently being tested in clinical trials across the country including at the Yale Cancer Medical Center. Head of the research team, Dr. Scott Gettinger has gotten PXD101 into FDA clinical testing. The drug has just completed the Phase II clinical trials; results have yet to be revealed.

Reported side effects of PXD101 include fatigue and nausea. However, this anti-angiogenesis drug has caused less severe side effects than radiation or chemotherapy.